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Evidence of the existence of major prostate cancer (PC)–susceptibility genes has been provided by multiple segregation
analyses. Although genomewide screens have been performed in over a dozen independent studies, few chromosomal
regions have been consistently identified as regions of interest. One of the major difficulties is genetic heterogeneity,
possibly due to multiple, incompletely penetrant PC-susceptibility genes. In this study, we explored two approaches
to overcome this difficulty, in an analysis of a large number of families with PC in the International Consortium
for Prostate Cancer Genetics (ICPCG). One approach was to combine linkage data from a total of 1,233 families
to increase the statistical power for detecting linkage. Using parametric (dominant and recessive) and nonparametric
analyses, we identified five regions with “suggestive” linkage (LOD score 11.86): 5q12, 8p21, 15q11, 17q21, and
22q12. The second approach was to focus on subsets of families that are more likely to segregate highly penetrant
mutations, including families with large numbers of affected individuals or early age at diagnosis. Stronger evidence
of linkage in several regions was identified, including a “significant” linkage at 22q12, with a LOD score of 3.57,
and five suggestive linkages (1q25, 8q13, 13q14, 16p13, and 17q21) in 269 families with at least five affected members.
In addition, four additional suggestive linkages (3p24, 5q35, 11q22, and Xq12) were found in 606 families with
mean age at diagnosis of 65 years. Although it is difficult to determine the true statistical significance of these
findings, a conservative interpretation of these results would be that if major PC-susceptibility genes do exist, they
are most likely located in the regions generating suggestive or significant linkage signals in this large study.
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Introduction
Familial clustering of prostate cancer (PC [MIM 176807])
has been consistently recognized for many years (re-
viewed by Isaacs and Xu [2002]). Segregation analyses
and twin studies strongly suggest that genetic factors ex-
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plain at least some of the familial aggregation of PC
(reviewed by Schaid [2004]). Research groups world-
wide have recruited families with multiple members with
PC and have performed linkage analyses to search for
PC-susceptibility genes. More than a dozen genomewide
screens have been performed (Easton et al. 2003), and
numerous regions have been suggested as harboring he-
reditary PC (HPC) genes. Furthermore, several genes in
regions linked to PC have been proposed as candidate
HPC genes, notably ELAC2 (MIM 605367), RNASEL
(MIM 180435), and MSR1 (MIM 153622) (Tavtigian et
al. 2001; Carpten et al. 2002; Xu et al. 2002).
Despite these extensive efforts, linkage findings sug-
gested by individual groups and proposed associations
with variants in candidate genes have not been repro-
ducibly replicated by other groups. The difficulties in
mapping PC genes have been widely discussed (Isaacs
and Xu 2002; Edwards and Eeles 2004; Ostrander et
al. 2004; Schaid 2004). Briefly, it is likely that multiple
genes predispose to PC and that no single gene is suf-
ficiently important to provide a reliable linkage signal
when a small number of families are analyzed. PC link-
age may be further complicated by phenocopies, par-
ticularly given the high prevalence of the disease and
widespread use of prostate-specific antigen screening.
These difficulties are inherent to PC-linkage studies, and,
although they cannot be completely overcome, several
approaches can be used to reduce their impact. One ap-
proach is to study a much larger number of families,
which should improve the statistical power to detect
regions containing genes that are mutated in a small
proportion of families. Another approach is to study
subsets of families with PC that are more likely both to
segregate mutations in genes conferring a strong PC risk
and to have a reduced number of phenocopies, such as
those with a large number of affected members and/or
affected members with early ages at diagnosis.
The International Consortium for Prostate Cancer Ge-
netics (ICPCG) was formed to facilitate the task of PC–
susceptibility gene identification through the combined
analyses of linkage data from families with PC. In the
present study, we describe the results from a combined
genomewide screen for PC-susceptibility genes among
1,233 PC-affected families within the ICPCG, the larg-
est study of its kind to date.
Methods
Ascertainment of Families
The overall ICPCG study population was described in
detail elsewhere (Schaid et al. 2005). All members of
the ICPCG recruited their study population, supported
through their own research funding. Ten ICPCG groups
participated in this combined genomewide screen, AC-
TANE (Anglo/Canadian/Texan/Australian/Norwegian/
European Union Biomed), BC/CA/HI (British Colum-
bia, California, and Hawaii), Johns Hopkins University
(JHU), Mayo Clinic, University of Michigan, PROGRESS
(Prostate Cancer Genetic Research Study, Fred Hutchin-
son Cancer Research Center), University of Tampere in
Finland, University of Ulm in Germany, University of
Umea˚ in Sweden, and University of Utah. There were
1,233 PC pedigrees in this combined analysis. The re-
search protocols and informed consent procedures were
approved by each group’s institutional review board.
Definition of Affection Status and Classification
of Pedigrees
Affected individuals were defined as “those men af-
fected with PC who had been confirmed by either medi-
cal records or death certificates.” Affected individuals
without either medical records or death-certificate con-
firmation were considered as having unknown affection
status (hence, instances of self-reported PC and of PC
status that was based solely on family-history interviews
were considered of unknown status). Because of this re-
stricted definition, some pedigrees had fewer affected men
than were previously reported in publications by the re-
spective groups. All men without a diagnosis of PC were
coded as having unknown affection status, regardless of
whether they had undergone screening for PC. Hence,
all analyses were based on the sharing of marker geno-
types among affected individuals, with no consideration
of the phenotype for the remaining subjects. Although
such an approach may result in some loss of power, it
provided a uniform approach across all participating
groups.
Genotyping and Consensus Genetic Map
Various methods were used by different groups to ge-
notype microsatellite markers in their respective genome-
wide screen, as described in detail elsewhere (Hsieh et
al. 2001; Cunningham et al. 2003; International AC-
TANE Consortium 2003; Janer et al. 2003; Lange et al.
2003; Schleutker et al. 2003; Wiklund et al. 2003, Xu
et al. 2003; Maier et al. 2005; Camp et al., in press).
Different sets of genomewide-screen markers were used
by these 10 groups (see individual references for com-
plete description of markers), with a range of informa-
tion contents of 0.38–0.57 across the various groups and
a total of 1,322 markers. To facilitate a combined link-
age analysis, we generated a consensus map by aligning
all these markers to the draft human reference sequence
(physical position) on the basis of the Human hg13 as-
sembly (released November 14, 2002). Ten of these mark-
ers could not be uniquely located in the human reference
sequence and were dropped from the combined analysis.
The genetic position of the aligned markers was pri-
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Table 1
Characteristics of Families
ICPCG MEMBER
MEAN AGE
AT DIAGNOSISa
(YEARS) NO. OF AFFECTED MEMBERS RACEb
TOTAL
NO. OF
FAMILIES65 165 2 3 4 5 White Black
ACTANE 41 21 18 32 11 3 64 0 64
BC/CA/HI 41 57 24 54 16 4 83 7 98
JHU 95 93 2 26 47 113 169 17 188
Mayo Clinic 72 87 70 58 21 10 158 0 159
PROGRESS 141 113 38 107 66 43 240 8 254
University of Michigan 103 73 55 76 29 16 158 16 176
University of Tampere 3 7 0 2 5 3 10 0 10
University of Ulm 84 55 60 42 29 8 139 0 139
University of Umea˚ 10 40 0 13 17 20 50 0 50
University of Utah 16 79 18 14 14 49 95 0 95
Total 606 625 285 424 255 269 1,166 48 1,233
a Information about family mean age at diagnosis was not available for two families.
b Nineteen families are from other ethnic groups, such as Asian, Hispanic, or Native American.
marily determined on the basis of the deCode map (Kong
et al. 2002). Among the 1,312 mapped markers, we were
able to find the deCode genetic position for 964 markers.
For the remaining 348 markers, for which only physical
position was available, we estimated their genetic posi-
tions by interpolation based on the flanking markers for
which both physical positions and deCode positions are
available.
Linkage-Analysis Methods
The combined linkage analysis was performed in two
stages. In the first stage, the linkage analyses were per-
formed by each of the 10 groups, by use of the same
definition of affection status and parametric model and
the same linkage programs and options. All linkage re-
sults were based on multipoint calculations implemented
in the Genehunter-Plus software (Kruglyak et al. 1996;
Kong and Cox 1997). Because of their large size, the Utah
pedigrees were selected from the larger set of all Utah
pedigrees with at least four subjects with PC with no
more than two meioses separating them (Camp et al.
2005); these pedigrees were then further trimmed to
allow analysis by Genehunter-Plus. The analysis per-
formed by each group was implemented by scripts pro-
vided by the ICPCG Data Coordinating Center (DCC),
to facilitate consistency and automation. Although dif-
ferent genomewide screen markers were used among
groups, the marker position was determined on the basis
of the consensus map described above; therefore, the
length of each chromosome was the same across all the
groups. The linkage was evaluated at a resolution of 1
cM for each chromosome. The output files containing
pedigree-specific linkage information at every cM across
the genome were sent to the DCC. In the second stage,
a combined analysis was performed at the DCC. For
nonparametric linkage analysis, the combined allele-shar-
ing LOD score was evaluated for each chromosome on
the basis of the family-specific allele sharing at each cen-
timorgan by use of the computer program ASM (Kong
and Cox 1997). For the parametric linkage analysis, the
combined LOD score with the assumption of hetero-
geneity (HLOD) was evaluated for each chromosome,
on the basis of the family-specific LOD score at each
centimorgan, by use of the computer program HOMOG
(Ott 1999). Throughout the present study, we used LOD
scores to describe HLODs for the results of parametric
analyses and allele sharing LODs for nonparametric
analyses.
The allele frequencies used were population specific;
that is, for each marker, allele frequencies were estimated
by counting alleles across all families within each indi-
vidual group, without consideration of genetic relation-
ships. Although not fully efficient, this provides straight-
forward, unbiased allele-frequency estimates. Because few
families within any participating group had a known non-
white racial background, allele frequencies were esti-
mated from the pool of all data within a group, without
consideration of race. Both nonparametric and para-
metric linkage analyses were performed. Allele-sharing
nonparametric linkage analysis was performed, because
that did not require specification of a model and would
be expected to have good power against a wide range of
alternative models. The linear allele-sharing model was
implemented using ASM (Kong and Cox 1997). Families
were weighted equally, and the score function “all” was
used, which provides more evidence of linkage than does
the “pairs” option whenever most affected individuals
in a pedigree share the same allele that is identical by
descent. For the parametric linkage analyses, a dominant
model and a recessive model were used. The dominant
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Figure 1 Combined genomewide screen for PC-susceptibility genes with use of nonparametric and parametric multipoint linkage analyses
among the entire set of 1,233 PC-affected families recruited from 10 ICPCG members. LOD scores obtained from parametric analysis with use
of a dominant model (blue line), a recessive model (red line), and nonparametric analysis (yellow line) are plotted by individual chromosome
for the whole genome.
model was similar to the one used to map HPC1 (MIM
601518) (Smith et al. 1996). The frequency of the sus-
ceptibility allele was assumed to be 0.003, with a pene-
trance of 0.001 for noncarriers and 1.0 for carriers. Un-
affected subjects were coded as having noninformative
phenotypes. The recessive model was similar to the domi-
nant model, except that the susceptibility-allele frequency
was set to 0.15 and the penetrance for heterozygous
carriers was set equal to the penetrance for homozygous
noncarriers. Stratified linkage analyses were also per-
formed in two predetermined subsets of families: 269
families with at least five affected members, and 606
families with family mean age at diagnosis of65 years.
The planned analyses were developed and approved by
members of the ICPCG.
We summarized our linkage results on the basis of the
proposed guidelines for reporting linkage results of a ge-
nomewide screen: a cutoff LOD score of 3.30 as “sig-
nificant” evidence of linkage and a cutoff LOD score of
1.86 as “suggestive” evidence of linkage (Lander and
Kruglyak 1995). On the basis of asymptotic arguments,
a LOD score of 3.30 is expected to occur 0.05 times in
a genome screen that makes use of a fully informative
marker set, and a LOD score of 1.86 is expected to occur
once by chance.
Results
Analyses of All Families
Table 1 summarizes the characteristics of the 1,233 PC-
affected families from 10 different ICPCG groups that
were included in the analysis. Fifty-one percent of fami-
lies had a mean age at onset of !65 years; 22% had five
or more affected family members.
We first performed a combined genomewide linkage
analysis of the complete set of 1,233 PC-affected fami-
lies, using parametric and nonparametric approaches.
Although no significant evidence of linkage was ob-
served in the genome, evidence of suggestive PC linkage
wasobserved at five chromosomal regions, 5q12, 8p21,
15q11, 17q21, and 22q12 (fig. 1 and table 2). The high-
est overall LOD score in the genome was 2.28 from the
nonparametric analysis, found near marker D5S2858 on
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Table 2
Chromosomal Regions with Suggestive Evidence of Linkage
POPULATION AND REGION
DISTANCE
FROM
PTER
cM
NEAREST
MARKER
ANALYSIS
TYPE LOD
1-LOD DROP
INTERVAL
Genetic
(cM)
Physical
(Mb)
Primary analysis: entire set of families ( ):Np 1,233
5q12 77 D5S2858 Nonparametric 2.28 66–96 43–78
8p21 46 D8S1048 Dominant 1.97 39–52 22–32
15q11 1 D15S817 Recessive 2.10 0–14 0–25
17q21 77 D17S1820 Dominant 1.99 66–85 35–54
22q12 42 D22S283 Dominant 1.95 35–47 29–37
Secondary analysis: subset of families with at least five affected family members ( ):np 269
1q25 184 D1S2818 Nonparametric 2.62 170–198 165–196
8q13 81 D8S543 Recessive 2.41 75–90 66–75
13q14 56 D13S1807 Recessive 2.27 42–67 39–71
16p13 34 D16S764 Nonparametric 1.88 19–46 9–23
17q21 77 D17S1820 Dominant 2.04 66–83 39–53
22q12 42 D22S283 Dominant 3.57 32–50 27–42
Secondary analysis: subset of families with mean age at diagnosis of 65 years ( ):np 606
3p24 57 D3S2432 Dominant 2.37 47–69 28–49
5q35 179 D5S1456 Dominant 2.05 166–193 162–174
11q22 102 D11S898 Recessive 2.20 89–112 81–111
Xq12 80 DXS7132 Dominant 2.30 62–90 40–85
Table 3
Support for Linkage from Each Group at Chromosomal Regions with Suggestive Linkage
POPULATION
LOD SCORE BY CHROMOSOMAL REGION AND MODEL
5q12 (77 cM)
Nonparametric
8p21 (46 cM)
Dominant
15q11 (1 cM)
Recessive
17q21 (77 cM)
Dominant
22q12 (42 cM)
Dominant
All groups ( )Np 1,233 2.28 1.97 2.10 1.99 1.95
ACTANE ( )np 64 .00 .00 .00 .00 .00
BC/CA/HI ( )np 98 1.17 .00 .26 .76 .00
JHU ( )np 188 .29 .16 .95 .72 1.28
Mayo Clinic ( )np 159 .32 .09 .00 .00 1.10
PROGRESS ( )np 254 .25 1.64 .64 .01 .00
University of Michigan ( )np 176 .01 .28 1.06 3.07 .13
University of Tampere ( )np 10 .00 .19 .00 .42 .02
University of Ulm ( )np 139 .38 .77 .04 .00 .00
University of Umea˚ ( )np 50 1.62 .00 .87 .00 .00
University of Utah ( )np 95 .27 .17 .00 .03 1.47
5q12 (77 cM from pter). The linkage results for each
individual family collection for each of these five chro-
mosomal regions are shown in table 3. As seen in table
3, with the exception of 17q21, the LOD scores for each
of the highlighted regions are higher in the combined
analysis than those observed in any individual group,
reaching a suggestive level of evidence only in the com-
bined family data.
Analyses of Subsets of Families
We also performed linkage analyses in subsets of fami-
lies that might be more likely to segregate genes con-
ferring strong PC risk: families with at least five affected
members or with family mean age at diagnosis of 65
years. As hypothesized, we found stronger evidence of
linkage among 269 families with at least five affected
members—one region with significant evidence of link-
age and four additional regions with suggestive evidence
of linkage (fig. 2 and table 2). The strongest evidence of
linkage in the genome was found at 22q12 with use of
the dominant model, with LOD score of 3.57 at 42 cM
(near marker D22S283). This LOD score exceeded the
criterion of significant evidence of linkage in the ge-
nomewide screen. Evidence of linkage at this region was
provided by multiple ICPCG groups (fig. 3). Of the 10
groups, 4 had a LOD score 11.0 at this region, including
a LOD score of 2.05 from the Mayo group, a LOD score
of 1.57 from the Michigan group, a LOD score of 1.31
from the Utah group, and a LOD score of 1.22 from
the JHU group. It is noted that linkage evidence at this
region was observed in the complete set of 1,233 fami-
lies (LOD score of 1.95 at 42 cM) and was strengthened
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Figure 2 Combined genomewide screen for PC-susceptibility genes with use of nonparametric and parametric multipoint linkage analyses
among 269 families with at least five affected members recruited from 10 ICPCG members. LOD scores obtained from parametric analysis
with use of a dominant model (blue line), a recessive model (red line), and nonparametric analysis (yellow line) are plotted by individual
chromosome for the whole genome.
in this subset. When families with at least five affected
family members were removed from the analysis, no
evidence of linkage at this region was found in the re-
maining 964 families. In addition to the 22q12 region,
five additional regions reached suggestive evidence of PC
linkage in this subset of families with at least five affected
family members (fig. 2 and table 2).
For 606 families with family mean age at diagnosis of
65 years, suggestive evidence of PC linkage was found
at four chromosomal regions (fig. 4 and table 2), with
the highest LOD score of 2.37 near marker D3S2432
at 3p24 (57 cM). The four PC linkages identified in this
subset of families were unique to the early-age-at-diag-
nosis subset. No evidence of linkage at these four regions
was observed in the complete set of 1,233 families.
Discussion
We have described results from the largest PC genome-
wide screen reported to date, with combined linkage data
from 1,233 PC-affected families collected by 10 different
groups in the ICPCG. From the primary analysis of the
entire set of the families, we identified five chromosomal
regions (5q12, 8p21, 15q11, 17q21, and 22q12) with
suggestive evidence of linkage. With one exception (i.e.,
17q21), the threshold for suggestive evidence of linkage
was reached only in the combined analysis, which em-
phasizes the advantage of this combined approach.
Importantly, we found significant evidence of linkage
at the 22q12 region in 269 families with at least five
affected members, a subset of PC-affected families that
is more likely to segregate mutations in genes conferring
a strong PC risk. Suggestive evidence of linkage at five
other regions (1q25, 8q13, 13q14, 16p13, and 17q21)
was also observed in this subset of families. In addition,
four additional regions (3p24, 5q35, 11q22, and Xq12)
were found to have suggestive evidence of PC linkage
in 606 families with family mean age at diagnosis of65
years.
We recognize that many of the regions identified in
this study may represent false positive findings due to
multiple tests in a genomewide screen and that it is dif-
ficult to dissect true linkages from false signals. On the
basis of the assumption of a fully informative marker
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Figure 3 Parametric linkage analysis of chromosome 22 among families with at least five affected members with use of the dominant
model. LOD scores are plotted for each of the 10 ICPCG groups.
map, LOD scores 13.30 or 1.86 would have been ex-
pected to occur 0.05 times and 1 time, respectively, in
a single genomewide screen. Here, we performed nine
genomewide screens (three in the primary analyses and
six in the subgroup analyses); this needs to be considered
when interpreting the results. However, these nine an-
alyses are not independent. Using the method of Camp
and Farnham (2001), we determined that the nine non-
independent analyses performed were equivalent to ∼5.2
independent genomewide screens. We therefore estimate
that, after correcting for multiple testing, regions with
a LOD score of 13.30 (significant evidence) in at least
one analysis would be expected 0.25 times in 5.2 inde-
pendent screens and regions with a LOD score of 11.86
(suggestive evidence), 5.2 times. Our empirical results
(one observed LOD score of 3.57 and 13 regions with
LOD scores 1.86) therefore exceeded the expectation
under the null hypothesis of no linkage. Furthermore,
these thresholds may be unduly conservative for the less-
than-informative real data used in these genomewide
screens. Although it is difficult to determine the true
statistical significance of these findings, a conservative
interpretation of these results would be that if major
PC-susceptibility genes do exist, they are most likely to
be located in the regions generating suggestive or sig-
nificant linkage signals. Therefore, results from this
analysis are likely to be helpful in prioritizing any efforts
to identify PC-susceptibility genes.
Lack of reproducibility among PC-linkage studies in
recent years demonstrates the difficulties faced in the
effort to identify PC-susceptibility genes with the link-
age approach (Isaacs and Xu 2002; Edwards and Eeles
2004; Ostrander et al. 2004; Schaid 2004). One of the
major difficulties is genetic heterogeneity due to multiple
but incompletely penetrant PC-susceptibility genes. Each
of these genes may be responsible for a small fraction
of PC-affected families. In this study, we planned two
approaches to address the impact that these difficulties
have on identification of PC linkage. One approach was
to perform linkage analysis in a large number of PC-
affected families, to increase the statistical power to de-
tect linkage. This approach led to the identification of
five regions with evidence suggestive of linkage in the
complete set of 1,233 families. However, the failure to
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Figure 4 Combined genomewide screen for PC-susceptibility genes with use of nonparametric and parametric multipoint linkage analyses
among 606 families with family mean age at diagnosis 65 years recruited from 10 ICPCG members. LOD scores obtained from parametric
analysis with use of a dominant model (blue line), a recessive model (red line), and nonparametric analysis (yellow line) are plotted by individual
chromosome for the whole genome.
identify significant linkage in the genome, even with this
large number of families, indicates a substantial degree
of genetic heterogeneity and suggests that this approach
alone is insufficient to uncover a significant signal if it
is present. Our second approach was to focus on sub-
sets of families that are more likely to segregate highly
penetrant mutations, including families with large num-
bers of affected individuals and/or early age at diag-
nosis. This latter approach appeared to be more effec-
tive; stronger evidence of linkage was found in several
regions among these subsets of families than from the
complete set of families. The most noteworthy finding
was the considerable increase in evidence of linkage at
22q12—from a LOD score of 1.95 (suggestive linkage)
in the complete set of families to a LOD score of 3.57
(significant linkage) in 269 families with at least five
affected members. It is important to note that the large
number of families in our combined study makes it pos-
sible to analyze sufficient numbers in each subset of
families. Linkage studies in families with large numbers
of affected individuals and/or early ages at diagnosis
have proved to be effective in identifying breast cancer–
susceptibility genes (Hall et al. 1990; Easton et al. 1993).
Three pieces of evidence from our study increase our
confidence that the linkage at 22q12 is due to PC-sus-
ceptibility gene(s) at this region. First, the LOD score
at this region reached the criterion of significant linkage.
The chance of observing this magnitude of LOD score
in the genome under a null hypothesis of no linkage is
!0.25 times in our study. Second, this linkage was iden-
tified in the families with at least five affected members,
a subset of families that is more likely to segregate mu-
tations in genes conferring strong PC risk. Third, the
evidence of linkage at this region was supported by mul-
tiple individual groups; of six groups with 10 such
large families, four had LOD scores 11 in this interval.
The relatively good reproducibility of this linkage find-
ing is an unusual observation in PC-linkage studies
(Easton et al. 2003). More than 129 known genes are
in the 1-LOD drop interval (29–37 Mb). An important
candidate gene, CHEK2 (MIM 604373), is outside the
interval, at ∼27 Mb.
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Because the mode of inheritance for PC is uncertain,
we performed linkage analysis using both parametric
(dominant or recessive) and nonparametric methods. In
general, evidence of PC linkage was consistently pro-
vided by both parametric and nonparametric methods,
although with different strengths at different regions.
Parametric analysis will have better power to detect
linkage when an assumed genetic model approximates
the underlying mode of inheritance of a disease suscep-
tibility gene (Clerget-Darpoux et al. 1986a, 1986b; Lio
and Morton 1997). Nonparametric analysis, by assess-
ment of allele sharing among affected individuals within
a pedigree, may have better power when the underlying
genetic model cannot be specified with any confidence
(Whittemore and Halpern 1994).
Most of the linkage regions identified in the present
study are broad. The information content of the marker
sets used in these analyses is generally low, particularly
since most of our families are small and often do not
include genotypes of all parents. Further genotyping at
a higher density, with use of either microsatellite mark-
ers or SNPs, should improve informativeness. An addi-
tional approach currently under way by the ICPCG in-
corporates clinical and pathological tumor variables in
the assignment of affected status, to emphasize clinically
aggressive disease in this large data set. Hopefully, these
approaches should help to confirm or refute the evi-
dence of linkage and narrow the regions of interest.
During the last decade, tremendous effort has been put
forth to identify major susceptibility genes for PC. Link-
age studies with smaller numbers of PC-affected fami-
lies have identified and implicated many chromosomal
regions that might harbor PC-susceptibility genes. The
large number of different regions that have been impli-
cated—and the general lack of reproducibility among
these studies—has provided a tenuous foundation for
subsequent PC-gene identification. In this context, results
from the current study, with a very large number of fam-
ilies in the overall analysis, provides a strong basis for
prioritizing regions for PC-gene identification.
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